Therapie mit Upadacitinib bei schwerem atopischen Ekzem bei Komorbidität einer ankylosierenden Spondylitis und reaktiven Uveitis

Zusammenfassung

Die atopische Dermatitis (AD) stellt mit einer Lebenszeitprävalenz von bis zu 20% die häufigste chronisch-entzündliche Hauterkrankung des Menschen dar. Die Leitsymptome sind quälender Pruritus und wiederkehrende ekzematöse Hautläsionen. Eine moderne therapeutische Option stellt die Modulation des JAK-STAT-Signalweges mit oralen JAK-Inhibitoren (JAKIs) dar. Wir berichten über einen 62-jährigen kaukasischen Patienten mit schwerer AD bei Komorbidität einer ankylosierenden Spondylitis und rezidivierenden Uveitiden, der sich nach Einleitung einer oralen Therapie mit Upadacitinib in anhaltender Remission sowohl der AD als auch der Komorbidität befindet.

Abstract

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in man, with a lifetime prevalence of up to 20%. Leading symptoms include i.a. agonizing pruritus and recurrent eczematous skin lesions. Modulation of the JAK-STAT signaling pathway with oral JAK inhibitors (JAKIs) is a novel therapeutic option. We report the case of a 62-year-old Caucasian patient with severe AD with comorbidity of ankylosing spondylitis and recurrent uveitis who is in sustained remission of both AD and comorbidities after receiving oral upadacitinib therapy.

Schlüsselwörter

Atopische Dermatitis - Upadacitinib - atopisches Ekzem - ankylosierenden Spondylitis - reaktive Uveitis

Keywords

atopic dermatitis - upadacitinib - atopic eczema - ankylosing spondylitis - reactive uveitis

Publication History

Article published online:
22 July 2022

• Literatur

• 1 Barbarot S, Auziere S, Gadkari A. et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy 2018; 73: 1284-1293 DOI: 10.1111/all.13401. (PMID: 29319189)
• 2 Silverberg JI, Barbarot S, Gadkari A. et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol 2021; 126: 417-428.e2 DOI: 10.1016/j.anai.2020.12.020. (PMID: 33421555)
• 3 Deckers IAG, McLean S, Linssen S. et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PLoS One 2012; 7: e39803 DOI: 10.1371/journal.pone.0039803. (PMID: 22808063)
• 4 Weidinger S, Beck LA, Bieber T. et al. Atopic dermatitis. Nat Rev Dis Primers 2018; 4: 1 DOI: 10.1038/s41572-018-0001-z. (PMID: 29930242)
• 5 von Kobyletzki LB, Thomas KS, Schmitt J. et al. What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey. Acta Derm Venereol 2017; 97: 86-90 DOI: 10.2340/00015555-2480. (PMID: 27305646)
• 6 Li H, Zhang Z, Zhang H. et al. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol 2021; 61: 324-338 DOI: 10.1007/s12016-021-08880-3. (PMID: 34338977)
• 7 Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergol Int 2022; 71: 40-46 DOI: 10.1016/j.alit.2021.10.004. (PMID: 34815171)
• 8 Guttman-Yassky E, Silverberg JI, Nemoto O. et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 2019; 80: 913-921.e9 DOI: 10.1016/j.jaad.2018.01.018. (PMID: 29410014)
• 9 Reich K, Kabashima K, Peris K. et al. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 2020; 156: 1333-1343 DOI: 10.1001/jamadermatol.2020.3260. (PMID: 33001140)
• 10 Simpson EL, Lacour J-P, Spelman L. et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255 DOI: 10.1111/bjd.18898. (PMID: 31995838)
• 11 Guttman-Yassky E, Teixeira HD, Simpson EL. et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151-2168 DOI: 10.1016/S0140-6736(21)00588-2. (PMID: 34023008)
• 12 Guttman-Yassky E, Thaçi D, Pangan AL. et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145: 877-884 DOI: 10.1016/j.jaci.2019.11.025. (PMID: 31786154)
• 13 Reich K, Teixeira HD, de Bruin-Weller M. et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169-2181 DOI: 10.1016/S0140-6736(21)00589-4. (PMID: 34023009)
• 14 Silverberg JI, Simpson EL, Thyssen JP. et al. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 2020; 156: 863-873 DOI: 10.1001/jamadermatol.2020.1406. (PMID: 32492087)
• 15 Simpson EL, Sinclair R, Forman S. et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396: 255-266 DOI: 10.1016/S0140-6736(20)30732-7. (PMID: 32711801)
• 16 Bieber T. Neue Hoffnung für Patienten mit atopischer Dermatitis. Ärztliches Journal. 2022 https://www.aerztliches-journal.de/medizin/dermatologie/dermatologie/haut/neue-hoffnung-fuer-patienten-mit-atopischer-dermatitis/c5f6d7399895e92cc3e8f80e6861b3dc/
• 17 van der Heijde D, Song I, Pangan AL. et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019; 394: 2108-2117 DOI: 10.1016/S0140-6736(19)32534-6. (PMID: 31732180)
• 18 Blauvelt A, Teixeira HD, Simpson EL. et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 2021; 157: 1047-1055 DOI: 10.1001/jamadermatol.2021.3023. (PMID: 34347860)
• 19 Brown MT, Bussell JK. Medication adherence: WHO cares?. Mayo Clin Proc 2011; 86: 304-314 DOI: 10.4065/mcp.2010.0575. (PMID: 21389250)
• 20 Silverberg JI, de Bruin-Weller M, Bieber T. et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J Allergy Clin Immunol 2022; 149: 977-987.e14 DOI: 10.1016/j.jaci.2021.07.036. (PMID: 34403658)
• 21 Paulose SA, Sherman SW, Dagi Glass LR. et al. Dupilumab-associated blepharoconjunctivitis. American Journal of Ophthalmology Case Reports 2019; 16: 100550 DOI: 10.1016/j.ajoc.2019.100550. (PMID: 31535057)